NASDAQ
PTIX

Protagenic Therapeutics

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Protagenic Therapeutics Stock Price

Vitals

Today's Low:
$1.69
Today's High:
$1.8999
Open Price:
$1.7501
52W Low:
$1.2488
52W High:
$2.8
Prev. Close:
$1.799
Volume:
9982

Company Statistics

Market Cap.:
$7.79 million
Book Value:
1.25
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-27.17%
Return on Equity TTM:
-50.53%

Company Profile

Protagenic Therapeutics had its IPO on 2016-01-05 under the ticker symbol PTIX.

The company operates in the Healthcare sector and Biotechnology industry. Protagenic Therapeutics has a staff strength of 0 employees.

Stock update

Shares of Protagenic Therapeutics opened at $1.75 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.69 - $1.9, and closed at $1.75.

This is a -2.75% slip from the previous day's closing price.

A total volume of 9,982 shares were traded at the close of the day’s session.

In the last one week, shares of Protagenic Therapeutics have slipped by -4.4%.

Protagenic Therapeutics's Key Ratios

Protagenic Therapeutics has a market cap of $7.79 million, indicating a price to book ratio of 0.9968 and a price to sales ratio of 0.

In the last 12-months Protagenic Therapeutics’s revenue was $0 with a gross profit of $0 and an EBITDA of $-3557758. The EBITDA ratio measures Protagenic Therapeutics's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Protagenic Therapeutics’s operating margin was 0% while its return on assets stood at -27.17% with a return of equity of -50.53%.

In Q2, Protagenic Therapeutics’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Protagenic Therapeutics’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-0.76 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Protagenic Therapeutics’s profitability.

Protagenic Therapeutics stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.1293. Its price to sales ratio in the trailing 12-months stood at 0.

Protagenic Therapeutics stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$6.92 million
Total Liabilities
$1.51 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Protagenic Therapeutics ended 2024 with $6.92 million in total assets and $0 in total liabilities. Its intangible assets were valued at $6.92 million while shareholder equity stood at $5.41 million.

Protagenic Therapeutics ended 2024 with $0 in deferred long-term liabilities, $1.51 million in other current liabilities, 434.00 in common stock, $-27705062.00 in retained earnings and $0 in goodwill. Its cash balance stood at $219435.00 and cash and short-term investments were $6.04 million. The company’s total short-term debt was $394,309 while long-term debt stood at $0.

Protagenic Therapeutics’s total current assets stands at $6.92 million while long-term investments were $0 and short-term investments were $5.82 million. Its net receivables were $0 compared to accounts payable of $158172.00 and inventory worth $0.

In 2024, Protagenic Therapeutics's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Protagenic Therapeutics paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.75
52-Week High
$2.8
52-Week Low
$1.2488
Analyst Target Price
$4

Protagenic Therapeutics stock is currently trading at $1.75 per share. It touched a 52-week high of $2.8 and a 52-week low of $2.8. Analysts tracking the stock have a 12-month average target price of $4.

Its 50-day moving average was $1.96 and 200-day moving average was $1.92 The short ratio stood at 0.29 indicating a short percent outstanding of 0%.

Around 5153.1% of the company’s stock are held by insiders while 774.5% are held by institutions.

Frequently Asked Questions About Protagenic Therapeutics

The stock symbol (also called stock or share ticker) of Protagenic Therapeutics is PTIX

The IPO of Protagenic Therapeutics took place on 2016-01-05

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$14.94
-1.32
-8.12%
ViewRay Inc (VRAY)
$0.01
-0
-3.33%
$24.47
0.21
+0.87%
$3523
-168.8
-4.57%
DHCNI (DHCNI)
$14.75
0.04
+0.27%
$34.16
0.47
+1.4%
$0.75
-0.01
-1.32%
$143.5
0.4
+0.28%
$331.75
-23.2
-6.54%
$1.76
-0.1
-5.38%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company’s lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

Address

149 Fifth Avenue, New York, NY, United States, 10010